Volitionrx Ltd (VNRX) - Total Liabilities
Based on the latest financial reports, Volitionrx Ltd (VNRX) has total liabilities worth $42.49 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Volitionrx Ltd to track the company's year-over-year net asset growth rate.
Volitionrx Ltd - Total Liabilities Trend (2004–2025)
This chart illustrates how Volitionrx Ltd's total liabilities have evolved over time, based on quarterly financial data. See VNRX FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Volitionrx Ltd Competitors by Total Liabilities
The table below lists competitors of Volitionrx Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aurora Mobile Ltd
NASDAQ:JG
|
USA | $316.94 Million |
|
Pavonine Co Ltd
KQ:177830
|
Korea | ₩80.81 Billion |
|
TEAM PLC
F:1WQ
|
Germany | €5.29 Million |
|
Dare Bioscience Inc
NASDAQ:DARE
|
USA | $29.63 Million |
|
Artmarket.com SA
PA:PRC
|
France | €5.80 Million |
|
GLORY HEALTH IND. HD-001
F:84R
|
Germany | €43.59 Billion |
|
Urteste SA
WAR:URT
|
Poland | zł16.75 Million |
|
UMS Holdings Bhd
KLSE:7137
|
Malaysia | RM8.35 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Volitionrx Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Volitionrx Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Volitionrx Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Volitionrx Ltd (2004–2025)
The table below shows the annual total liabilities of Volitionrx Ltd from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $42.49 Million | +19.68% |
| 2024-12-31 | $35.51 Million | -3.15% |
| 2023-12-31 | $36.66 Million | +71.15% |
| 2022-12-31 | $21.42 Million | +119.30% |
| 2021-12-31 | $9.77 Million | -0.90% |
| 2020-12-31 | $9.86 Million | +38.97% |
| 2019-12-31 | $7.09 Million | +32.61% |
| 2018-12-31 | $5.35 Million | +14.61% |
| 2017-12-31 | $4.67 Million | +31.17% |
| 2016-12-31 | $3.56 Million | +113.35% |
| 2015-12-31 | $1.67 Million | -45.59% |
| 2014-12-31 | $3.06 Million | +120.48% |
| 2013-12-31 | $1.39 Million | +0.51% |
| 2012-12-31 | $1.38 Million | +19.60% |
| 2011-12-31 | $1.16 Million | +907.47% |
| 2010-12-31 | $114.77K | +3.42% |
| 2009-12-31 | $110.98K | +11.83% |
| 2008-12-31 | $99.24K | +20.06% |
| 2007-12-31 | $82.66K | +41.34% |
| 2006-12-31 | $58.48K | -19.93% |
| 2005-12-31 | $73.04K | +13.95% |
| 2004-12-31 | $64.10K | -- |
About Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleos… Read more